Jennifer Jill Wilkes, MD, MSCE

Jennifer Jill Wilkes, MD, MSCE

Cancer and Blood Disorders Center, Leukemia and Lymphoma Program, Apheresis

On staff since September 2016

Academic Title: Acting Assistant Professor

    • Christy Redmond, WA 08.28.17

      Dr. Jen Wilkes has been a wonderful oncologist--walking us through our son's new cancer diagnosis and ensuing battle. Her empathy for her patients, compassion, and expertise in her subject matter make her a great ally for parents. She is tireless and passionate in her work and shows great care for the children she treats. We are always happy to meet with her and so glad to have her on our team!

    • James Stanwood, WA 06.21.17

      Dr. Wilkes has been my daughter's primary oncologist since shortly after her diagnosis, 7 months ago. She has a tremendous amount of knowledge and has always been extremely patient with us through out the whole process. She has guided through a difficult diagnosis and a long treatment path. All the information that she gave us was very clear and concise, and she has made herself available when we need her. Dr. Wilkes also shows a sense of empathy that i find to be rare in the medical field. I highly recommend anyone considering her care.

  • Other Publications

    • Wolfson JA, Bhatia S, Ginsberg J, Becker LK, Bernstein D, Henk HJ, Lyman GH, Nathan PC, Puccetti D, Wilkes JJ, Winestone LE, Kenzik KM
      Expenditures among young adults with acute lymphoblastic leukemia by site of care.
      33465248 Cancer, 2021 June 1 : 127(11)1901-1911
    • Chow EJ, Doody DR, Wilkes JJ, Becker LK, Chennupati S, Morin PE, Winestone LE, Henk HJ, Lyman GH
      Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.
      33283555 Leukemia & lymphoma, 2021 May : 62(5)1203-1210 PMCID:PMC8106632
    • Wilkes JJ, Lyman GH, Doody DR, Chennupati S, Becker LK, Morin PE, Winestone LE, Henk HJ, Chow EJ
      Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies.
      32822255 JCO oncology practice, 2021 March : 17(3)e406-e415 PMCID:PMC8189599
    • Larsen GY, Brilli R, Macias CG, Niedner M, Auletta JJ, Balamuth F, Campbell D, Depinet H, Frizzola M, Hueschen L, Lowerre T, Mack E, Paul R, Razzaqi F, Schafer M, Scott HF, Silver P, Wathen B, Lukasiewicz G, Stuart J, Riggs R, Richardson T, Ward L, Huskins WC, IMPROVING PEDIATRIC SEPSIS OUTCOMES COLLABORATIVE INVESTIGATORS.
      Development of a Quality Improvement Learning Collaborative to Improve Pediatric Sepsis Outcomes.
      33328337 Pediatrics, 2021 Jan. : 147(1) PMCID:PMC7874527
    • Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, Heym KM, Katz AJ, Kelsh MA, Sposto R, Tu H, Tuglus CA, Verma A, Vinti L, Wilkes JJ, Zubarovskaja N, Zugmaier G, von Stackelberg A, Sun W
      Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
      32094465 Leukemia, 2020 Sept. : 34(9)2473-2478 PMCID:PMC7449874
    • Cahen VC, Li Y, Getz KD, Elgarten CW, DiNofia AM, Wilkes JJ, Winestone LE, Huang YV, Miller TP, Gramatges MM, Rabin KR, Fisher BT, Aplenc R, Seif AE
      Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment.
      32391940 Pediatric blood & cancer, 2020 May 11 : e28315
    • Phillips CA, Razzaghi H, Aglio T, McNeil MJ, Salvesen-Quinn M, Sopfe J, Wilkes JJ, Forrest CB, Bailey LC
      Development and evaluation of a computable phenotype to identify pediatric patients with leukemia and lymphoma treated with chemotherapy using electronic health record data.
      31207054 Pediatric blood & cancer, 2019 Sept. : 66(9)e27876 PMCID:PMC7135896
    • Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA
      Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
      29728694 Leukemia, 2018 Nov. : 32(11)2316-2325 PMCID:PMC6224404
    • Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, Shyr Y, Moons KGM, Sulis ML, Friedman DL
      Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia.
      28542918 Cancer, 2017 Oct. 1 : 123(19)3781-3790 PMCID:PMC5610619
    • Winestone LE, Getz KD, Miller TP, Wilkes JJ, Sack L, Li Y, Huang YS, Seif AE, Bagatell R, Fisher BT, Epstein AJ, Aplenc R
      The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia.
      27862214 American journal of hematology, 2017 Feb. : 92(2)141-148 PMCID:PMC5733783
    • Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Tolbert VP, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS
      Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.
      27437864 Pediatric blood & cancer, 2016 Nov. : 63(11)1943-8 PMCID:PMC7451261
    • Rao P, Li Y, Getz KD, Miller TP, Huang YS, Wilkes JJ, Seif AE, Bagatell R, Fisher BT, Gracia C, Aplenc R
      Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.
      27618636 Cancer, 2016 Sept. 12
    • Wilkes JJ, Hennessy S, Xiao R, Rheingold S, Seif AE, Huang YS, Vendetti N, Li Y, Bagatell R, Aplenc R, Fisher BT
      Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy.
      27246140 Clinical lymphoma, myeloma & leukemia, 2016 July : 16(7)404-410.e1 PMCID:PMC4925172
    • Ipe TS, Wilkes JJ, Hartung HD, Westhoff CM, Chou ST, Friedman DF
      Severe hemolytic transfusion reaction due to anti-D in a D+ patient with sickle cell disease.
      25171447 Journal of pediatric hematology/oncology, 2015 March : 37(2)e135-7 PMCID:PMC4333075
    • Wilkes JJ, Leckerman KH, Coffin SE, Keren R, Metjian TA, Hodinka RL, Zaoutis TE
      Use of antibiotics in children hospitalized with community-acquired, laboratory-confirmed influenza.
      19874761 The Journal of pediatrics, 2009 March : 154(3)447-9
    • Wilkes JJ, Zaoutis TE, Keren R, Desai B, Leckerman KH, Hodinka RL, Metjian TA, Coffin SE
      Treatment with oseltamivir in children hospitalized with community-acquired, laboratory-confirmed influenza: review of five seasons and evaluation of an electronic reminder.
      19301375 Journal of hospital medicine, 2009 March : 4(3)171-8

  • Presentations Title Event Location Date
    Standard Practice: Management of Infections in the Immunocompromised Host.” Seattle Children’s Hospital Seattle Children's Hospital Seattle, WA July 2020
    Standard Practice: Management of Infections in the Immunocompromised Host.” Seattle Children’s Hospital Seattle Children's Hospital Seattle, WA July 2019
    Quality Improvement Scholars Program: Inpatient Febrile Neutropenia Seattle Children’s Hospital Grand Rounds Seattle, WA May 2019
    Does Hospital Volume Influence Outcomes in Pediatric Acute Lymphoblastic Leukemia? A Window into Healthcare Delivery Cincinnati Children’s Hospital Cincinnati, OH Feb. 2016
    Does Hospital Volume Influence Outcomes in Pediatric Acute Lymphoblastic Leukemia? A Window into Healthcare Delivery University of Texas Southwestern Dallas, TX Feb. 2016
    Standard Practice: Management of Infections in the Immunocompromised Host Seattle Children's Hospital Seattle, WA Dec. 2015
    Hospital Volume Metrics and Induction Mortality in Pediatric, Adolescent and Young Adult Acute Leukemia: An Update Alex’s Lemonade Stand Foundation Young Investigator Symposium Philadelphia, PA Oct. 2015
    Hospital Volume Metrics and Induction Mortality in Pediatric, Adolescent and Young Adult Acute Leukemia Alex’s Lemonade Stand Foundation Young Investigator Symposium Philadelphia, PA Oct. 2014
    Are variations in antimicrobial use associated with case volume of acute lymphoblastic leukemia patients? Pediatric Pharmacology Training Grant Presentation, Eunice Kennedy Shriver National Institute of Child Health and Human Development Rockville, MD Oct. 2013
  • Grant Title Grantor Amount Award Date
    Establishing cohorts of newly diagnosed leukemia and lymphoma patients for pharmacoepidemiology and practice questions Alex’s Lemonade Stand Foundation July 1, 2018 - Dec. 31, 2020
    Chronic myelogenous leukemia (CML) and use of Tyrosine Kinase Inhibitors (TKI) in Claims Data. Stand Up to Cancer (SU2C) Nov. 2017 - Jan. 2019
    Evaluation of clinical outcomes relevant to the care of pediatric acute myeloid leukemia during periods of neutropenia. Home or Away from Home Sept. 2016 - Jan. 2019
    Hospital volume and pediatric leukemia AHRQ July 2015 - June 2016
    Hospital volume and pediatric leukemia in adolescents and young adults Alex’s Lemonade Stand Foundation July 2014 - June 2016
    Postdoctoral Training Program in Obstetric and Pediatric Pharmacoepidemiology NICHD July 2012 - June 2016

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

University of Pennsylvania School of Medicine, Philadelphia

Residency

Children's Hospital of Philadelphia, Philadelphia

Fellowship

Pediatric Hematology Oncology, Children's Hospital of Philadelphia, Phildelphia

Clinical Interests

Leukemia and lymphoma

Research Description

Quality improvement, health services and epidemiology in pediatric oncology